|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33.
2021.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Rubin KM and Lawrence DP: Your patient
with melanoma: Staging, prognosis, and treatment. Oncology
(Williston Park). 23 (Suppl 8):S13–S21. 2009.PubMed/NCBI
|
|
3
|
Michielin O, van Akkooi ACJ, Ascierto PA,
Dummer R and Keilholz U: ESMO Guidelines Committee. Electronic
address: simpleclinicalguidelines@esmo.org.
Cutaneous melanoma: ESMO clinical practice guidelines for
diagnosis, treatment and follow-up†. Ann Oncol. 30:1884–1901.
2019.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mandalà M and Voit C: Targeting BRAF in
melanoma: Biological and clinical challenges. Crit Rev Oncol
Hematol. 87:239–255. 2013.PubMed/NCBI View Article : Google Scholar
|
|
5
|
El Jammal T, Pavic M, Gerfaud-Valentin M,
Jamilloux Y and Sève P: Sarcoidosis and cancer: A complex
relationship. Front Med (Lausanne). 7(594118)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Seve P, Schott AM, Pavic M, Broussolle C,
Gilis L and Thomas L: Sarcoidosis and melanoma: A referral center
study of 1,199 cases. Dermatology. 219:25–31. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Cohen Aubart F, Lhote R, Amoura A, Valeyre
D, Haroche J, Amoura Z and Lebrun-Vignes B: Drug-induced
sarcoidosis: An overview of the WHO pharmacovigilance database. J
Intern Med. 288:356–362. 2020.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Gkiozos I, Kopitopoulou A, Kalkanis A,
Vamvakaris IN, Judson MA and Syrigos KN: Sarcoidosis-like reactions
induced by checkpoint inhibitors. J Thorac Oncol. 13:1076–1082.
2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Rubio-Rivas M, Moreira C and Marcoval J:
Sarcoidosis related to checkpoint and BRAF/MEK inhibitors in
melanoma. Autoimmun Rev. 19(102587)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Dimitriou F, Frauchiger AL,
Urosevic-Maiwald M, Naegeli MC, Goldinger SM, Barysch M, Franzen D,
Kamarachev J, Braun R, Dummer R and Mangana J: Sarcoid-like
reactions in patients receiving modern melanoma treatment. Melanoma
Res. 28:230–236. 2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Wilmott JS, Haydu LE, Menzies AM, Lum T,
Hyman J, Thompson JF, Hersey P, Kefford RF, Scolyer RA and Long GV:
Dynamics of chemokine, cytokine, and growth factor serum levels in
BRAF-mutant melanoma patients during BRAF inhibitor treatment. J
Immunol. 192:2505–2513. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Green JS, Norris DA and Wisell J: Novel
cutaneous effects of combination chemotherapy with BRAF and MEK
inhibitors: A report of two cases. Br J Dermatol. 169:172–176.
2013.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Park JJ, Hawryluk EB, Tahan SR, Flaherty K
and Kim CC: Cutaneous granulomatous eruption and successful
response to potent topical steroids in patients undergoing targeted
BRAF inhibitor treatment for metastatic melanoma. JAMA Dermatol.
150:307–311. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Jansen YJ, Janssens P, Hoorens A, Schreuer
MS, Seremet T, Wilgenhof S and Neyns B: Granulomatous nephritis and
dermatitis in a patient with BRAF V600E mutant metastatic melanoma
treated with dabrafenib and trametinib. Melanoma Res. 25:550–554.
2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Winkler JK, Buder-Bakhaya K, Ellert E,
Herpel E, Martens UM, Enk A and Hassel JC: Acute heart failure as a
result of granulomatous myocarditis: Case report on a patient with
metastatic melanoma treated with dabrafenib and trametinib. J Eur
Acad Dermatol Venereol. 32:e31–e32. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Rueda-Rueda T, Sánchez-Vicente JL,
Moruno-Rodríguez A, Molina-Socola FE, Martínez-Borrego AC and
López-Herrero F: Uveitis and serous retinal detachment secondary to
systemic dabrafenib and trametinib. Arch Soc Esp Oftalmol (Engl
Ed). 93:458–462. 2018.PubMed/NCBI View Article : Google Scholar : (In English,
Spanish).
|
|
17
|
Korman AM, Nisar MS and Somach SC:
Subclinical granulomas in benign skin lesions heralding the onset
of BRAF and MEK inhibitor-associated granulomatous dermatitis in a
patient with metastatic melanoma. JAAD Case Rep. 4:722–724.
2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Giet G, Lebas E, Rorive A, Arrese JE and
Nikkels AF: Granulomatous reactions from tattoos following BRAF
inhibitor therapy. Case Rep Dermatol. 11:101–107. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Huynh S, Lheure C, Franck N, Goldman-Lévy
G, Aractingi S, Dupin N, Kramkimel N and Guégan S: Induced
sarcoid-like reactions in patients with metastatic melanoma treated
with dabrafenib and trametinib: A monocentric retrospective study.
Melanoma Res. 30:317–320. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Boutros A, Schiavi C, Cecchi F, Spagnolo
F, Guadagno A, Tanda ET, Giusti F, Murdaca G and Queirolo P: Case
report: Immune-related toxicity during adjuvant treatment with BRAF
plus MEK inhibitors in a melanoma patient. Front Immunol.
11(579523)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Adam A, Thomas L, Bories N, Zaharia D,
Balme B, Freymond N and Dalle S: Sarcoidosis associated with
vemurafenib. Br J Dermatol. 169:206–208. 2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Hui Ong EL, Sinha R, Jmor S and Fearfield
L: BRAF inhibitor-associated granulomatous dermatitis: A report of
3 cases. Am J Dermatopathol. 41:214–217. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Assan F, Schlemmer F, Assie JB, Mahevas M,
Sustronck P, Ortonne N, Velter C, Fardet L and Zehou O: Atypical
systemic sarcoid-like granulomatosis in two patients treated with
BRAF and MEK inhibitors. Eur J Dermatol. 29:556–557.
2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lheure C, Kramkimel N, Franck N,
Laurent-Roussel S, Carlotti A, Queant A, Goldwasser F, Avril MF and
Dupin N: Sarcoidosis in patients treated with vemurafenib for
metastatic melanoma: A paradoxical autoimmune activation.
Dermatology. 231:378–384. 2015.PubMed/NCBI View Article : Google Scholar
|
